On June 6, 2022 PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc. ("Akili"), a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, reported that industry veteran Matt Franklin will join the company in the newly created role of President and Chief Operating Officer, effective June 21, 2022 (Press release, PureTech Health, JUN 6, 2022, View Source [SID1234615605]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As President and COO, Franklin will join Eddie Martucci, Akili’s Chief Executive Officer, and the company’s executive leadership team to scale the organization and bring Akili’s diverse pipeline of cognitive treatments to market, with an initial focus on the commercial launch of EndeavorRx. He will lead the day-to-day operations of the company, and oversee Commercial, Product, Engineering, Medical and People Operations.

Franklin brings more than two decades of experience across business, commercial and strategic marketing in the diagnostics, life sciences and technology industries leading and evolving innovation. Most recently, Franklin served as General Manager of the Precision Oncology business unit at Exact Sciences. Previously, Franklin was the Chief Commercial Officer at Thrive Earlier Detection Corp, where he led the go-to-market strategy development for their ground-breaking multi-cancer early detection assay. In addition, Franklin served as the Chief Business Officer for ArcherDX, a growth-stage molecular diagnostics company, where he was responsible for establishing and scaling the global sales, customer support, marketing, market access, business development and corporate development teams. Prior to ArcherDX, Franklin served as the Senior Vice President of Global Marketing and Clinical Product Strategy at Foundation Medicine where he led the global launch of three products in three years, including the company’s first liquid biopsy offering and the first FDA-approved, CMS-covered, comprehensive genomic profiling companion diagnostic test. Franklin held progressive leadership roles overseeing novel interventional medical devices at Boston Scientific, culminating in his running global strategic planning, product development and marketing for the company’s cardiovascular division.

On June 6, 2022 JSR Corporation (Head Office: Minato-ku, Tokyo, Representative Director and CEO: Eric Johnson, JSR Corporation) reported that it has entered into a facility usage agreement with AuB Co., Ltd. (AuB), a company engaged in the study of intestinal microbiota in athletes, for the Collaborative Lab, a collaborative research facility with startups, which is located in a new research laboratory "JSR Bioscience and Informatics R & D center (JSR BiRD)" in Kawasaki City, Kanagawa Prefecture, which opened last July (Press release, JSR, JUN 6, 2022, View Source [SID1234615601]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AuB, founded in Oct 2015, is a company that conducts food-tech business based on research into the intestinal bacteria of athletes. Representative director Keita Suzuki is a former top athlete who was a professional player for the Urawa Red Diamonds, a J.League soccer team, and also played for Japan’s national team. Since its foundation, the company has analyzed the intestinal environment of more than 750 athletes (1,700 samples), developed proprietary materials based on this knowledge, and developed a business to sell them externally. In the future, the company is also considering entering the pharmaceutical field.

JSR is developing its life science business as a core business, focusing on diagnostic reagent materials, bioprocess materials, and drug discovery support businesses. At the same time, JSR is engaged in research on the microbiome, etc. as next-generation technology research, and is pursuing the realization of innovation that leads to new products and services required for a healthy and long-lasting society. Through joint research with AuB in collaboration labs, we aim to further accelerate next generation research and commercialize it.

On June 6, 2022 EpiAxis Therapeutics reported as we return to face-to-face biotech conferences after more than two years of virtual attendance (Press release, EpiAxis Therapeutics, JUN 6, 2022, View Source;utm_medium=rss&utm_campaign=epiaxis-executives-attend-us-biotech-conferences [SID1234615600]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chairman Dr David Fuller is currently representing EpiAxis at the ASCO (Free ASCO Whitepaper) 2022 Annual Meeting in Chicago; while CEO Dr Jeremy Chrisp will attend the BIO International Convention from June 13-16, 2022 at San Diego Convention Center.

The American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), the world’s premier oncology gathering, opened in Chicago on June 3 for the first time since 2019, bringing the largest crowd of cancer care leaders together since the start of the pandemic. The 2022 ASCO (Free ASCO Whitepaper) Annual Meeting Program is offering presentations on the latest research in cancer care and extensive networking opportunities. This year’s program will feature over 200 sessions complementing the meeting’s theme: Advancing Equitable Cancer Care Through Innovation.

ASCO organisers said last week more than 36,000 people had registered for the conference and 80% were planning to attend the meeting in person.

"It is great to see ASCO (Free ASCO Whitepaper) return to Chicago and have the opportunity to interact with with industry colleagues again after the COVID-19 pandemic," Dr Fuller said. "Each year, the ASCO (Free ASCO Whitepaper) conference brings together oncologists from all around the globe and is attended by medical, educational and industrial stakeholders involved in the field of oncology worldwide. It’s an invaluable opportunity to share EpiAxis’ epigenetic advances with a highly engaged audience."

Dr Jeremy Chrisp is looking forward to attending the 2022 BIO International Convention later this month. The convention will feature more than 100 interactive sessions across four days, covering a variety of therapeutic areas, business development, digital health, patient advocacy and next generation biotherapeutics.

"We are seeking new investors to advance our pioneering epigenetic program into the clinic and the Bio International Convention will be an excellent opportunity to update the industry on our progress in the epigenetic space," Dr Chrisp said.

"We are looking to continue our discussions with potential pharma partners who are receptive to our novel first-in-class oncology therapeutics. Epigenetics is an emerging and active therapeutic area and offers the prospect of a less toxic cancer treatment by re-programming both cancer and immune cells for superior outcomes.

"Importantly, we believe through face-to-face discussion, the underlying value in our programs can best be communicated. EpiAxis is now moving into the next phase of development and is seeking to raise US $12million (tranched) to take us from lead candidate selection through IND filing and an initial Phase 1/2 dose escalation expansion study."

On June 6, 2022 OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, provides an update on its CD39 program: Innate Pharma reported that IPH5201, the CD39 blocking monoclonal antibody developed in collaboration with AstraZeneca, will advance into a Phase 2 clinical trial in lung cancer(Press release, OREGA BIOTECH, JUN 6, 2022, View Source [SID1234615566]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

About IPH5201 antibody

IPH5201 is a humanized CD39 blocking antibody. OREGA Biotech commenced the CD39 program at its inception in 2010, then entered into an exclusive and worldwide License Agreement with Innate Pharma in 2016. The lead antibody has been further partnered with AstraZeneca in 2018. AstraZeneca conducted a multicenter, open-label, dose-escalation Phase 1 trial in advanced solid tumors (NCT04261075) with IPH5201 alone or in combination with durvalumab (anti PD-L1 antibody).

Jeremy Bastid, Chief Executive Officer of OREGA Biotech, commented "We are very pleased that IPH5201 antibody is now progressing into a Phase 2 trial; this represents a major achievement for our company. Our academic cofounders are also very proud of having been involved in the discovery of the immunoregulatory role of the adenosine pathway in cancer, the components of which are now being targeted in multiple clinical trials".

On June 5, 2022 Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, reported that yesterday on June 4, 2022, in the Industry Expert Theater during the ASCO (Free ASCO Whitepaper) 2022 conference, Dr. Marnix Bosch made a presentation discussing the Company’s DCVax-L technology for personalized dendritic cell vaccines, the Sawston, UK facility, the manufacturing technology, the development of automation, and preparations for manufacturing scale-up (Press release, Northwest Biotherapeutics, JUN 5, 2022, View Source [SID1234615615]). In addition, a video presentation about the DCVax-L clinical program was screened in the Company’s exhibit booth in the ASCO (Free ASCO Whitepaper) Exhibit Hall.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These presentations are now available online at View Source

The Industry Expert Theater is not an official event of the ASCO (Free ASCO Whitepaper) Annual Meeting. It is not sponsored, endorsed or accredited by ASCO (Free ASCO Whitepaper), CancerLinq, or Conquer Cancer the ASCO (Free ASCO Whitepaper) Foundation. It is not CME-accredited.